# Molecular Imaging Study of Harmine/DMT: a Basic Research Approach

> **NCT06252506** · PHASE1 · COMPLETED · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 17 (actual)

## Conditions studied

- Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine

## Interventions

- **DRUG:** N,N-dimethyltryptamine (DMT) + harmine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06252506
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-22
- **Primary completion:** 2025-02-17
- **Final completion:** 2025-03-05
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2025-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06252506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06252506, "Molecular Imaging Study of Harmine/DMT: a Basic Research Approach". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06252506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*